Immix Biopharma, Inc. 8K

Immix Biopharma, Inc. agreed to sell 16,778,524 registered common shares to underwriters led by Morgan Stanley for a public offering closing on May 22, 2026.

Immix Biopharma, Inc. entered into an underwriting agreement dated May 21, 2026 with Morgan Stanley & Co. LLC, as representative of the underwriters, pursuant to which the company will issue and sell 16,778,524 shares of its common stock, par value $0.0001 per share, under an effective Form S-3 shelf registration statement (File No. 333-292665) at a purchase price of $8.4036 per share to the underwriters, who will offer the shares to the public at an initial price of $8.94 per share, with closing of the offering scheduled for May 22, 2026 subject to customary conditions, representations, warranties, and covenants.

Filing Facts

CIK

1873835

Ticker

IMMX

Form

8K

Source Type

sec

Accession

0001493152-26-024872

Alert Tier

7